Cognition Therapeutics, Inc. Aligns with FDA on Pivotal Phase 3 Trial of Zervimesine in Dementia with Lewy Bodies

Cognition Therapeutics said it aligned with the FDA on key elements of a planned Phase 3 registrational study for dementia with Lewy bodies, including patient selection, dose, duration, and endpoints. The study is expected to enroll participants, but the article text ends before specifying the population or providing enrollment figures.